Overview

A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetic (PK-the study of the way a drug enters and leaves the blood and tissues over time) characteristics of bortezomib when administered intravenously in Taiwanese participants with multiple myeloma (cancer of the types of cells normally found in bone marrow).
Phase:
Phase 4
Details
Lead Sponsor:
Johnson & Johnson Taiwan Ltd
Treatments:
Bortezomib